MGMT and central nervous system cancer: Although several new molecules such as IDH1 mutation, MGMT promoter methylation, and 1p/19q chromosome codeletion have been applied for diagnosis and treatment in gliomas, the prognosis of patients remains unsatisfactory, which drives us to explore more effective and credible factors.